Dispensed Prescriptions for Quetiapine and Other Second-generation Antipsychotics in Canada from 2005 to 2012: a Descriptive Study

Overview

Journal CMAJ Open

Specialty General Medicine

Date 2014 Dec 9

PMID 25485247

Citations 33

Authors

Tamara Pringsheim

David M Gardner

Affiliations

Soon will be listed here.

Abstract

Background: The use of antipsychotic drugs, particularly quetiapine, has increased at an unprecedented rate in the last decade, primarily in relation to nonpsychotic indications. This increased use is concerning because of the high rates of metabolic and extrapyramidal side effects and inadequate monitoring of these complications. The purpose of this study was to measure the use of quetiapine and other second-generation antipsychotics by primary care physicians and psychiatrists and the most common diagnoses associated with quetiapine recommendations.

Methods: We analyzed data on antipsychotic use from the IMS Brogan Canadian CompuScript Database and the Canadian Disease and Treatment Index, with a focus on quetiapine. We looked at the number of dispensed prescriptions for second-generation antipsychotics written by primary care physicians and psychiatrists and the diagnoses associated with recommendations for quetiapine from 2005 to 2012.

Results: Between 2005 and 2012, there was a 300% increase in dispensed prescriptions for quetiapine ordered by family physicians: from 1.04 million in 2005 to 4.17 million in 2012. In comparison, dispensed prescriptions from family physicians for risperidone increased 37.4%: from 1.39 million in 2005 to 1.91 million in 2012; those for olanzapine increased 37.1%, from 0.97 million in 2005 to 1.33 million in 2012. Dispensed prescriptions for quetiapine ordered by psychiatrists increased 141.6%: from 0.87 million in 2005 to 2.11 million in 2012. The top 4 diagnoses associated with quetiapine in 2012 were mood disorders, psychotic disorders, anxiety disorders and sleep disturbances. A 10-fold increase in quetiapine recommendations for sleep disturbances was seen over the study period, with almost all coming from family physicians.

Interpretation: These findings indicate a preferential increase in the use of quetiapine over other antipsychotic drugs and show that most of the increased use is a result of off-label prescribing by family physicians.

Citing Articles

Second-Generation Antipsychotics Induce Metabolic Disruption in Adipose Tissue-Derived Mesenchymal Stem Cells Through an aPKC-Dependent Pathway.

Varalda M, Venetucci J, Nikaj H, Kankara C, Garro G, Keivan N Cells. 2025; 13(24.

PMID: 39768174 PMC: 11674800. DOI: 10.3390/cells13242084.

Hepatotoxicity of antipsychotics: an exploratory pharmacoepidemiologic and pharmacodynamic study integrating FAERS data and receptor-binding affinities.

Zeiss R, Schonfeldt-Lecuona C, Connemann B, Hafner S, Gahr M Front Psychiatry. 2024; 15:1479625.

PMID: 39469476 PMC: 11513306. DOI: 10.3389/fpsyt.2024.1479625.

Changes in Sedative Use in British Columbia, Canada from 2012 to 2021: A Drug Utilization Study.

Thompson W, Kim J, Carney G, Otte J, Dormuth C J Gen Intern Med. 2024; .

PMID: 39414735 DOI: 10.1007/s11606-024-09065-2.

Distribution of quetiapine between serum and whole blood in therapeutic drug-monitoring specimens.

Breivik H, Tunset M, Schou M, Frost J J Anal Toxicol. 2024; 48(3):180-184.

PMID: 38407283 PMC: 10977622. DOI: 10.1093/jat/bkae006.

Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effects.

Roth W, Dadiomov D, Chu M Ther Adv Drug Saf. 2023; 14:20420986231213173.

PMID: 38074415 PMC: 10702410. DOI: 10.1177/20420986231213173.

References

Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A . Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl). 2004; 174(3):421-9. DOI: 10.1007/s00213-003-1759-5. View

Katzman M, Brawman-Mintzer O, Reyes E, Olausson B, Liu S, Eriksson H . Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2010; 26(1):11-24. DOI: 10.1097/YIC.0b013e32833e34d9. View

Cutler A, Montgomery S, Feifel D, Lazarus A, Astrom M, Brecher M . Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009; 70(4):526-39. DOI: 10.4088/jcp.08m04592. View

Jing Y, Guo Z, Kalsekar I, Forbes R, Hebden T, Thase M . Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). Int Clin Psychopharmacol. 2012; 28(2):87-90. DOI: 10.1097/YIC.0b013e32835ce232. View

Murphy A, Gardner D, Cooke C, Kisely S, Hughes J, Kutcher S . Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry. 2013; 13:198. PMC: 3737046. DOI: 10.1186/1471-244X-13-198. View

Pasquini M, Speca A, Biondi M . Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics. 2009; 50(2):159-61. DOI: 10.1176/appi.psy.50.2.159. View

Philip N, Mello K, Carpenter L, Tyrka A, Price L . Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry. 2008; 20(1):15-20. DOI: 10.1080/10401230701866870. View

Cipriani A, Koesters M, Furukawa T, Nose M, Purgato M, Omori I . Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 10:CD006533. PMC: 4169791. DOI: 10.1002/14651858.CD006533.pub2. View

Pringsheim T, Panagiotopoulos C, Davidson J, Ho J . Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011; 20(3):218-33. PMC: 3143700. View

10.

Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J . Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai. 2010; 93(6):729-34. View

11.

Kim D, Staab J . Quetiapine discontinuation syndrome. Am J Psychiatry. 2005; 162(5):1020. DOI: 10.1176/appi.ajp.162.5.1020. View

12.

Pringsheim T, Lam D, Patten S . The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009. J Child Adolesc Psychopharmacol. 2011; 21(6):537-43. DOI: 10.1089/cap.2010.0145. View

13.

Coe H, Hong I . Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother. 2012; 46(5):718-22. DOI: 10.1345/aph.1Q697. View

14.

Merideth C, Cutler A, She F, Eriksson H . Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2011; 27(1):40-54. DOI: 10.1097/YIC.0b013e32834d9f49. View

15.

Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S . Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2009; 13(3):305-20. DOI: 10.1017/S1461145709990423. View

16.

Patten S, Esposito E, Carter B . Reasons for antidepressant prescriptions in Canada. Pharmacoepidemiol Drug Saf. 2007; 16(7):746-52. DOI: 10.1002/pds.1385. View

17.

Depping A, Komossa K, Kissling W, Leucht S . Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010; (12):CD008120. DOI: 10.1002/14651858.CD008120.pub2. View

18.

Komossa K, Depping A, Gaudchau A, Kissling W, Leucht S . Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010; (12):CD008121. DOI: 10.1002/14651858.CD008121.pub2. View

19.

Simon N, Connor K, Lebeau R, Hoge E, Worthington 3rd J, Zhang W . Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008; 197(4):675-81. DOI: 10.1007/s00213-008-1087-x. View

20.

Traynor K . FDA advisers wary of expanding quetiapine use: clinicians air concerns about metabolic effects, tardive dyskinesia. Am J Health Syst Pharm. 2009; 66(10):880, 882. DOI: 10.2146/news090042. View